Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dermabay is a science-first, formulation-led Indian skincare brand founded in 2022 by pharmaceutical scientist Dr. Divneet Kaur and healthcare strategist Simran Kaur. Headquartered in Ludhiana, Punjab, the company develops clinical-grade skincare products specifically optimized for Indian skin types and environmental stressors like pollution and UV radiation. Their product line includes sunscreens, serums, and moisturizers formulated with high-performance active ingredients such as encapsulated retinol, specialized peptides, and stable antioxidants. Dermabay operates as a direct-to-consumer (D2C) brand, emphasizing radical transparency, pharmacological integrity, and research-backed results over traditional cosmetic marketing. The company leverages advanced formulation technologies to ensure skin absorption and biological compatibility, positioning itself as a leader in the emerging Indian cosmeceutical market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DermaBay.